FDA Approves First Obesity Pill, Wegovy Maker Novo Nordisk Leads the Charge
Table of Contents
The U.S. Food and Drug Administration on Monday granted approval for the first-ever GLP-1 pill designed to treat obesity, a landmark decision poised to expand access to treatment for millions. Novo Nordisk, the manufacturer of the popular weight loss injection Wegovy, anticipates launching the oral medication in early 2026.
A New Era in Obesity Treatment
The approval marks a meaningful shift in the landscape of obesity care,offering a more convenient option to injections. Starting in early January, a 1.5-milligram starting dose will be available through pharmacies and select telehealth providers, with a cash price of $89 per month. Higher doses will be rolled out over the following months.
Of the approval sent Novo Nordisk’s stock soaring, with shares gaining approximately 10% in after-hours trading Monday. Beyond weight loss,the FDA also authorized the pill to reduce the risk of major cardiovascular events – including death,heart attack,and stroke – in adults with obesity and pre-existing cardiovascular disease.This expanded indication mirrors the approval label for Wegovy, which contains the same active ingredient, semaglutide.
Expanding Access Through Oral Administration
“What we’ve learned through years of research is that having an oral option really kind of opens up, activates and motivates different segments to seek treatment,” explained a Novo Nordisk executive during a pre-approval interview. “To have that conversation with their doctor to see if this is something that might be right for them.” The company believes the convenience of a pill will encourage more individuals to explore treatment options,building upon the success of their existing injectable therapies.
Novo Nordisk Gains Ground in a Booming Market
This approval provides Novo Nordisk with a crucial advantage over its primary competitor, Eli Lilly, which currently dominates the market with its obesity injection zepbound and is actively developing its own oral medication. The GLP-1 market, which these two pharmaceutical giants have pioneered, is projected to reach a staggering $100 billion by 2030, according to some analysts.
Wall Street analysts are optimistic about the potential of oral GLP-1 medications, with Goldman Sachs estimating thay could capture 24% – or roughly $22 billion – of the global weight loss drug market by 2030. BMO Capital Markets analyst Evan Seigerman noted the approval represents a “much-needed win” for Novo Nordisk, particularly considering recent challenges to its market share dominance in the incretin class of drugs. Incretins are treatments that mimic gut hormones, such as GLP-1.
Clinical Trial Results Demonstrate Efficacy
The FDA’s decision was based on a phase three clinical trial involving over 300 adults with obesity, but without diabetes. Results presented at a medical conference in 2024 showed that a 25-milligram dose of the oral semaglutide led to an average weight loss of up to 16.6% after 64 weeks. Even when analyzing patients who discontinued the medication, the average weight loss remained significant at 13.6%.
The pill demonstrated slightly greater effectiveness than an experimental oral drug currently under review by the FDA from Eli Lilly.Though, a key difference lies in the administration requirements: Novo Nordisk’s pill necessitates a 30-minute waiting period before eating or drinking, while Eli Lilly’s treatment, which is not a peptide medication, is absorbed more readily and does not require such restrictions.
Addressing the Rise of Compounded Medications
Novo Nordisk also addressed the growing concern surrounding unapproved, compounded versions of GLP-1 medications. A company spokesperson stated that the pill’s pricing aims to align with the cost of these compounded alternatives,which gained popularity during recent shortages of Ozempic and Wegovy. Patients turned to these cheaper options when faced with limited insurance coverage or supply constraints.
However, the spokesperson expressed alarm over the presence of illegitimate ingredients in some compounded medications, emphasizing the risks associated with illegally mass-marketed products. The FDA has largely curtailed the legal production of compounded semaglutide following the resolution of the earlier shortages. “It continues to be alarming and disturbing for us,” the spokesperson said, referring to the potential health risks posed by these unregulated products.
